Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers

NCT06605404 is registered in ClinicalTrials.gov with Paradigm Health as lead sponsor.

NCT NCT06605404
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06605404 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Molecular Residual Disease in Solid Tumors: A Prospective Study to Collect Clinical Data and Biospecimens to Support Discovery and Development of Cancer Biomarkers
Lead sponsor
Paradigm Health
Phase
Observational
Overall status
Recruiting
Start date
January 8, 2025
Completion date
April 30, 2032
Enrollment
1,350 (estimated)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer, gastric and gastroesophageal junction (gej) adenocarcinoma, melanoma (skin cancer), mix of solid tumors (most), muscle invasive bladder urothelial carcinoma, nsclc (non-small cell lung cancer), pancreatic (exocrine only)